The main appeal still lies with sabirnetug, which could offer meaningful upside if Phase 2 data supports a viable path into ...

Acumen Pharmaceuticals' ACU193 shows promise as a potential treatment for early-stage Alzheimer's Disease, targeting amyloid beta oligomers with a more favorable safety profile. Q2 earnings show ...

Detailed price information for Acumen Pharmaceuticals Inc (ABOS-Q) from The Globe and Mail including charting and trades.

Collaboration Management Control Solutions Qatar and Acumen have announced the availability of Acumen Risk - a full-featured, 'easy-to-use' cost and schedule risk analysis tool.The global launch of ...

Acumen Pharmaceuticals (NASDAQ:ABOS) said its Phase 2 ALTITUDE-AD trial of sabirnetug remains on track, with top-line results ...

Phoenix CPM today announced a new collaboration and integration with Acumen Fuse, Acumen Risk and Acumen 360. The integration of Phoenix Project Manager and the Acumen suite of schedule and risk tools ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...